Cost of disorders of the brain in Europe 2010

Gustavsson, Anders; Svensson, Mikael; Jacobi, Frank; Allgulander, Christer; Alonso, Jordi; Beghi, Ettore; Dodel, Richard; Ekman, Mattias; Faravelli, Carlo; Fratiglioni, Laura; Gannon, Brenda; Jones, David Hilton; Jennum, Poul; Jordanova, Albena; Jönsson, Linus; Karampampa, Korinna; Knapp, Martín; Kobelt, Gisela; Kurth, Tobias; Lieb, Roselind; Linde, Mattias; Ljungcrantz, Christina; Maercker, Andreas; Melin, Beatrice; Moscarelli, Massimo; Musayev, Amir; Norwood, Fiona; Preisig, Martin; Pugliatti, Maura; Rehm, Jüergen; Salvador‐Carulla, Luis; Schlehofer, Brigitte; Simon, Roland; Steinhausen, Hans-Christoph; Stovner, Lars Jacob; Vallat, Jean‐Michel; Bergh, Peter Van den; Os, Jim van; Vos, Pieter E.; Xu, Weili; Wittchen, Hans‐Ulrich; Jönsson, Bengt; Olesen, Jes

doi:10.1016/j.euroneuro.2011.08.008

Cited by 1,339 publications

(866 citation statements)

References 391 publications

Supporting

Mentioning

801

Contrasting

Unclassified

Order By: Relevance

“…These anxiety-related disorders are associated with a diminished sense of well-being, elevated rates of unemployment and relationship breakdown, and elevated suicide risk [1][2][3]. Together, they have a lifetime prevalence in the USA of 29 % [4], the highest of any mental disorder, and constitute an immense social and economic burden [5,6].…”

Section: Introductionmentioning

confidence: 99%

Cannabidiol as a Potential Treatment for Anxiety Disorders

et al. 2015

View full text Add to dashboard Cite

Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD's potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder when administered acutely; however, few studies have investigated chronic CBD dosing. Likewise, evidence from human studies supports an anxiolytic role of CBD, but is currently limited to acute dosing, also with few studies in clinical populations. Overall, current evidence indicates CBD has considerable potential as a treatment for multiple anxiety disorders, with need for further study of chronic and therapeutic effects in relevant clinical populations.

show abstract

Section: Introductionmentioning

confidence: 99%

Cannabidiol as a Potential Treatment for Anxiety Disorders

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Depression and anxiety disorders are highly prevalent, cause great suffering and disability, and have a large impact on society (Murphy et al, 2004;Wittchen et al, 2011;Buist-Bouwman et al, 2006;Murray & Lopez, 1997b;Murray & Lopez, 1997a).…”

Section: Introductionmentioning

confidence: 99%

“…However, they place a high demand on healthcare services (Gustavsson et al, 2011;Nutt, 2011;Smit et al, 2006). Offering these treatments in a more concise form without compromising effectiveness might mitigate this problem (Cape et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

The clinical effectiveness of concise cognitive behavioral therapy with or without pharmacotherapy for depressive and anxiety disorders; a pragmatic randomized controlled equivalence trial in clinical practice

Meuldijk

Carlier

Vliet

et al. 2016

Contemporary Clinical Trials

View full text Add to dashboard Cite

. (2016). The clinical effectiveness of concise cognitive behavioral therapy with or without pharmacotherapy for depressive and anxiety disorders; a pragmatic randomized controlled equivalence trial in clinical practice. Contemporary Clinical Trials, 47 131-138. See next page for additional authorsThe clinical effectiveness of concise cognitive behavioral therapy with or without pharmacotherapy for depressive and anxiety disorders; a pragmatic randomized controlled equivalence trial in clinical practice Abstract Background: Depressive and anxiety disorders contribute to a high disease burden. This paper investigates whether concise formats of cognitive behavioral-and/or pharmacotherapy are equivalent with longer standard care in the treatment of depressive and/or anxiety disorders in secondary mental health care. Methods: A pragmatic randomized controlled equivalence trial was conducted at five Dutch outpatient Mental Healthcare Centers (MHCs) of the Regional Mental Health Provider (RMHP) 'Rivierduinen'. Patients (aged 18-65 years) with a mild to moderate anxiety and/or depressive disorder, were randomly allocated to concise or standard care. Data were collected at baseline, 3, 6 and 12 months by Routine Outcome Monitoring (ROM). Primary outcomes were the Brief Symptom Inventory (BSI) and the Web Screening Questionnaire (WSQ). We used Generalized Estimating Equations (GEE) to assess outcomes. Results: Between March 2010 and December 2012, 182 patients, were enrolled (n = 89 standard care; n = 93 concise care). Both intention-to-treat and per-protocol analyses demonstrated equivalence of concise care and standard care at all time points. Severity of illness reduced, and both treatments improved patient's general health status and subdomains of quality of life. Moreover, in concise care, the beneficial effects started earlier. Discussion: Concise care has the potential to be a feasible and promising alternative to longer standard secondary mental health care in the treatment of outpatients with a mild to moderate depressive and/or anxiety disorder. For future research, we recommend adhering more strictly to the concise treatment protocols to further explore the beneficial effects of the concise treatment. Moreover, in concise care, the beneficial effects started earlier.

show abstract

“…An "epilepsy" diagnosis comes with a host of "comorbidities" ranging from significant developmental and cognitive complications, mood and anxiety disorders, and social stigma, to seizure-related injuries. This leads to the staggering annual health care cost of $15.5 billion in the USA alone [2], and over €13.8 billion in Europe [3]. Mortality risk triples for all patients with epilepsy, and the rate of sudden death is increased at least 20 times in those with uncontrolled seizures [4].…”

mentioning

confidence: 99%